SARS-CoV-2 Virus Evolution Advisory Committee (TAG-VE) from time to time to evaluate and evaluate the SARS-CoV-2 mutation, and the combination of clear mutations and various factors have been identified as contagious. The TAG-VE was convened on November 26, 2021 to investigate the SARS-CoV-2 mutation, B.1.1.529.
Amendment B.1.1.529 was first responded to WHO on November 24, 2021 in South Africa. Outbreak cases in South Africa are described with three particular themes in published cases, most recently with the predominance of delta anomalies. Recently, the virus has spread rapidly with the discovery of the B.1.1.529 mutation. The first confirmed cases of B.1.1.529 were from patients registered on November 9, 2021.
There are so many variations of this change, some confusing. Starter Proof describes the continuous bet of recycling with this difference compared to other VOCs. By all accounts, the cost of this gap appears to be rising in almost all parts of South Africa. Currently, SARS-CoV-2 PCR diagnostics are aware of these changes. Many labs have found that one of our effective targets is unreliable for most commonly used PCR assays (called S-positive release or S-positive target failure), and it is now the symbol of the difference between these lines. Sequencing agreement. Using this technique, this uncertainty can show the difference in value more quickly than previous floods of pollutants, suggesting that this disadvantage would be beneficial.
Further research is ongoing and TAG-VE will continue to measure this change. WHO will discuss new findings in the case of members and communities.
Based on the evidence base showing the negative effects of COVID-19 transmission studies, TAG-VE should select this mutation as the COV for the WHO, who selected B.1.1.529 as: COV called Omicron.
In this capacity, countries are approached to do the following:
- developing research and sequencing efforts to better understand the course of SARS-CoV-2 variations.
submit general genomic groups and related metadata to an open accessible information database such as GISAID.
- Report the first cases / cases related to WHO VOC pollution through the IHR system.
- if there are limitations and work with the global local area, conduct field research and laboratory tests to understand the possible effects of volatile organic compounds on COVID-19, disease transmission studies, severity, severity of general welfare and social measures, demonstration strategies, indestructible reactions, balance antifungal agents or other related properties.
People are cautioned to limit their gambling with COVID-19 longer, including demonstrating general well-being and social measures such as wearing well-covered veils, hand hygiene, physical removal, further improving indoor ventilation, flood prevention, and vaccinations. . For information, WHO has working definitions for SARS-CoV-2 Variant of Interest (VOI) and Variant of Concern (VOC).
SARS-CoV-2 VOI is a variant of SARS-CoV-2:
- with inherited changes that are expected or expected to affect the characteristics of the infection, such as infection, disease severity, uncontrollable rest, analytical or regenerative leakage; en
- identified as the cause of large local transmission in the area as in different COVID-19 groups, in different countries with growing relative dominance in the neighborhood by expanding the number of cases in the long term, as further clear epidemiological implications of the recommendations emerging risk to global overall welfare.
SARS-CoV-2 VOC is a variant of SARS-CoV-2 that meets the definition of VOI (see above) and has been shown by relative assessment to be associated with at least one of the related changes in one site. level. worldwide general benefit of interest:
- Distribution of infectious as a modification of COVID-19 in the study of disease transmission; of
- prolongation of the injury or change in the clinical manifestation of the disease; of
- reduced viability of general well-being and social measures such as available diagnostics, immunization, therapy